Dividend Win Wednesday: Gold Down, Semiconductors at 89% Off, and Energy Insiders Add

This Week's Setup

Newmont and ConocoPhillips hold the top dividend ranks while gold trades down from recent highs and energy draws fresh insider capital across three names.

KLA Corporation sits at Pixie Rank 2 with a 13.2% free cash flow yield at an 89.5% drawdown, the deepest discount on the screen this week.

The S&P 500 CAPE remains at 38.9, a level that historically favors income strategies with operational resilience and cash-return discipline.

Quick Scan

The 8 Names

1. Newmont Corporation (NEM)

Dividend yield: 1.1% | Payout ratio: 15.7% | 52w drawdown: -31.9%

Newmont delivers a 7.4% FCF yield at an 11.9 price-to-earnings multiple while gross margin stands at 53.2%, the strongest operational efficiency in the top five names. The company generated 21.3% revenue growth year-over-year as production scales across its global asset base.

Peter Toth executed a full sale of 18,394 shares on July 6, the only insider transaction in the trailing 30 days. The position sits 31.9% below the 52-week high while Argus Research published "Gold Prices Down from the Clouds," signaling commodity headwinds that compress realized prices for producers in the near term.

Interest coverage of 50.5 times and net debt-to-EBITDA of negative 0.2 indicate a fortress balance sheet, but the drawdown zone remains deep and Citigroup cut the price target to $125 from $150 this week, reflecting a recalibration of precious-metals sentiment across the sell side.

2. KLA Corporation (KLAC)

Dividend yield: 4.3% | Payout ratio: 29.6% | 52w drawdown: -89.5%

KLA trades at a 6.1 price-to-earnings ratio and 13.2% FCF yield while delivering 66.5% return on invested capital, the highest in the entire screen. Revenue grew 23.9% year-over-year and the normalized 10-year P/E of 11.7 implies a long-cycle valuation anchor near current levels despite the semiconductor drawdown.

Bren Higgins executed two purchases on July 2 and July 6, and Mary Beth Wilkinson added shares July 2, marking three insider transactions in the first week of the month. Intel, KLA, Lam Research, Marvell, and Micron shares rallied sharply this week on news of SpaceX supply-chain wins and Micron guidance revisions, creating momentum after months of sector compression.

The 89.5% drawdown is the deepest on the screen, and the $1,855 analyst target implies 756% upside, a spread that signals either extraordinary dislocation or a stale consensus model. Next earnings land July 28 with estimates of $1.00 EPS on $3.6 billion revenue; any guide-down extends the correction.

3. ConocoPhillips (COP)

Dividend yield: 2.9% | Payout ratio: 51.3% | 52w drawdown: -14.0%

ConocoPhillips combines a 5.1% FCF yield with 13.5% return on invested capital and an interest coverage ratio of 11.3, offering operational stability while trading at a moderate 14% drawdown. Revenue growth of 7.7% year-over-year aligns with production expansion as the company scales its Permian and Lower 48 positions.

Andres Felipe Mejia Cardona, Silvina Vatnick, and Sylvia Escovar Gomez each added shares on June 22, the most recent insider activity recorded. ExxonMobil and energy equities rallied after Rubio stated Iran is "not serious" about nuclear talks, raising the probability of sustained sanctions pressure and tighter global oil supply through year-end.

Net debt-to-EBITDA of 0.73 and a 51.3% payout ratio leave limited buffer if crude prices compress below $70 in the back half of 2026. Susquehanna lifted the target to $155 from $152, but the 22.2% implied upside reflects cautious positioning after the sector's first-half volatility.

4. Novartis AG (NVS)

Dividend yield: 3.1% | Payout ratio: 64.7% | 52w drawdown: -9.5%

Novartis operates at a 75.8% gross margin, the second-highest profitability structure on the screen, while generating 9.6% revenue growth and 16.0% return on invested capital. The 5.2% FCF yield supports the 3.1% dividend at a 64.7% payout ratio, offering cash-return stability through patent cliffs and biosimilar pressure.

The analyst target of $153.87 implies negative 0.2% upside from the current $154.21 price, reflecting sell-side skepticism that the oncology and ophthalmology franchises can offset generic erosion in cardiovascular and diabetes portfolios. Net debt-to-EBITDA of 1.75 constrains M&A optionality while the company navigates regulatory approvals for its CAR-T pipeline expansions.

Interest coverage of 15.3 times mitigates refinancing risk, but the 9.5% drawdown leaves little margin if European pharma multiples compress further under pricing pressure from national health systems and U.S. biosimilar competition.

5. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: -1.4%

Biogen generates a 6.6% FCF yield at a 21.8 price-to-earnings multiple while trading near its 52-week high with only a 1.4% drawdown. The company posted 2.2% revenue growth year-over-year and maintains a 75.7% gross margin, positioning its Alzheimer's and multiple sclerosis franchises for stable cash generation as Leqembi uptake accelerates.

Insider activity logged 10 total transactions over the past six months with a net addition of 3 shares, all purchases and zero sales, signaling management conviction ahead of the July 29 earnings release. Guggenheim raised the price target to $280 from $260, citing upside from Leqembi commercial traction and biosimilar launches in international markets.

The company pays no dividend and carries a 0.0% payout ratio, disqualifying it from traditional income strategies despite the strong FCF profile. Net debt-to-EBITDA of 0.64 and interest coverage of 6.8 times are the weakest credit metrics in the biotech cohort, a constraint if the Alzheimer's franchise underperforms consensus expectations or faces reimbursement headwinds.